UCL Technology Fund

Type

Venture Capital

Status

Active

Location

London, United Kingdom

Total investments

37

Average round size

22M

Portfolio companies

26

Rounds per year

4.62

Lead investments

9

Follow on index

0.30

Exits

4

Areas of investment
BiotechnologyE-CommerceSoftwareInformation TechnologyArtificial IntelligenceMachine LearningHealth CareManufacturingMedicalTherapeutics

Summary

The leading representative office of defined VC is situated in the London. The company was established in Europe in United Kingdom.

The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Opposing the other organizations, this UCL Technology Fund works on 9 percentage points less the average amount of lead investments. The fund is constantly included in 2-6 investment rounds annually. The common things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2018.

Among the various public portfolio startups of the fund, we may underline Orchard Therapeutics, Hazy, MediaGamma Among the most popular fund investment industries, there are Genetics, Artificial Intelligence. The fund has exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United Kingdom. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.

The overall number of key employees were 1.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the UCL Technology Fund, startups are often financed by UCLB, Syncona Partners LLP, Nesta Impact Investments. The meaningful sponsors for the fund in investment in the same round are London Co-Investment Fund, AI Seed, UCLB. In the next rounds fund is usually obtained by Syncona Partners LLP, Venrock, UCLB.

Show more

Investor highlights

Industry focus
GoodsBiotech/Life Sciences
Stage focus
Pre-SeedSeedSeries ASeries BSeries C
Geo focus
Generalist
Check size
314K — 9M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
37
Lead investments
9
Exits
4
Rounds per year
4.62
Follow on index
0.30
Investments by industry
  • Biotechnology (12)
  • Artificial Intelligence (11)
  • Health Care (9)
  • Software (9)
  • Machine Learning (8)
  • Show 46 more
Investments by region
  • United Kingdom (36)
  • United States (1)
Peak activity year
2018

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Group Appearance index
0.89
Avg. company exit year
3
Strategy success index
0.40

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Apollo Therapeutics 17 Jun 2021 Biotechnology, Health Care, Medical, Therapeutics Early Stage Venture 137M England, United Kingdom, United Kingdom
Bloomsbury Genetic Therapies 07 Oct 2022 Biotechnology, Pharmaceutical, Biopharma Seed 6M Cambridgeshire, Cambridge, United Kingdom
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.